8 May 2026
On a landmark day for the Duchenne muscular dystrophy community, we are delighted to share that the National Institute for Health and Care Excellence (NICE) has recommended the treatment givinostat (brand name Duvyzat) for use on the NHS in England. In final draft...
7 May 2026
Today, Solid Biosciences announced that the first participant has been dosed in the Phase 3 Impact Duchenne clinical trial, a randomised, double-blind, placebo-controlled study evaluating SGT-003 for Duchenne. Clinical trial sites are currently active in Australia and...
30 Apr 2026
We are delighted to share that psychosocial guidelines for Duchenne muscular dystrophy have been published by Duchenne Care UK. We are proud to be a key funder of the psychosocial programme, which is part of a wider, multi‑year national effort by Duchenne Care UK to...
12 Mar 2026
Solid Biosciences has announced a positive clinical update on the SGT-003 gene therapy programme. This update includes interim safety and biomarker data from the ongoing Phase 1/2 Inspire Duchenne clinical trial. To date, 40 participants have been dosed with SGT-003...
12 Feb 2026
The pychosocial working group gathered around Duchenne Care UK’s newly published education guidelines for teachers. Pictured from left: Duchenne Care UK project coordinator Adam Kerr; Pathfinders advocacy officer Sam Cornelius-Light; consultant child and...
12 Jan 2026
The Duchenne Research Fund is delighted to share that NICE has recognised the respiratory care guidelines that were created and published by the DMD Care UK programme that we fund. This follows NICE’s recognition of DMD Care UK’s cardiac guidelines in...
9 Dec 2025
Scottish Medicines Consortium (SMC) has approved the treatment givinostat for use on the NHS in Scotland, for children aged 6+ who are still able to walk at the start of treatment. Givinostat (also known by its brand name Duvyzat) was approved for market authorisation...
18 Nov 2025
The World Muscle Society has awarded the Duchenne Research Fund prize at the annual WMS international congress, supporting a talented researcher in the Duchenne arena. The winner at the 30th anniversary congress in Vienna, Austria, was Luca Bello, associate professor...
10 Nov 2025
Solid Biosciences has released an update on its Inspire Duchenne clinical trial, which is investigating the safety, tolerability and efficacy of its gene therapy candidate SGT-003. The Phase 1/2, open-label study has now dosed 23 patients, and expects to have dosed 30...
7 Sep 2025
On World Duchenne Awareness Day 2025, the Duchenne Research Fund is delighted to share that NICE has recognised the cardiac care guidelines that were created and published by the DMD Care UK programme that we fund. As stated on NICE’s website: “We think...